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Phosphonated chelates for nuclear imaging†
Sabah Abada,a,b Alexandre Lecointre,a,b Câline Christine,*a,b
Laurence Ehret-Sabatier,a,b Falk Saupe,c Gertraud Orend,c David Brasse,d,e
Ali Ouadi,d,e Thomas Hussenet,c Patrice Laquerrière,d,e Mourad Elhabiri*f and
Loïc J. Charbonnière*a,b
A series of bis-, tris- and tetra-phosphonated pyridine ligands is presented. In view of their potential use as
chelates for radiopharmaceutical applications, the physico-chemical properties of the ligands and of their Co(II),
Ni(II), Cu(II), and Zn(II) complexes were studied by means of potentiometry and UV-Vis absorption spectroscopy.
The pKa values of the ligands and of the complexes, as well as the stability constants for the formation of the
complexes, are presented. The kinetic aspects of the formation of Cu(II) complexes and of their dissociation in
acidic media were studied by means of stopped ﬂow experiments, and the stability of the Cu(II) complex toward
reduction to Cu(I) was investigated by cyclic voltammetry and by titration with diﬀerent reducing agents. The
diﬀerent thermodynamic and kinetic aspects of the polyphosphonated ligands were compared with regard to
the impact of the number of phosphonic acid functions. Considering the very promising properties for com-
plexation, preliminary SPECT/CT imaging experiments were carried out on mice with 99mTc using the bis- and
tetra-phosphonated ligands L2 and L1. Finally, a bifunctional version of chelate L1, L*, was used to label MTn12,
a rat monoclonal antibody with both speciﬁcity and relatively high aﬃnity for murine tenascin-C. The labeling
was monitored by MALDI/MS spectrometry and the aﬃnity of the labeled antibody was checked by immuno-
staining experiments. After chelation with 99mTc, the 99mTc-L*-MTn12 antibody was injected into a transgenic
mouse with breast cancer and the biodistribution of the labeled antibody was followed by SPECT/CT imaging.
Introduction
The development of radiopharmaceuticals is currently receiv-
ing much interest for diagnostic imaging and therapy in
nuclear medicine, particularly in two major imaging modal-
ities, Positron Emission Tomography (PET) and Single Photon
Emission Computed Tomography (SPECT). Many radioiso-
topes are used for these two techniques, among them 64Cu
(T1/2 = 12.7 h, β
+: 17.8%, Eβ+ = 656 keV; β
−: 38.4%, Eβ− =
573 keV) is particularly promising for PET,1–5 and 99mTc (T1/2 =
6 h, pure γ-emitter, Eγ = 140 keV) is the radionuclide of choice
for SPECT imaging.2,5,6
Although these radionuclides can be used for their intrinsic
properties, as in the case of thyroid imaging with 99mTcO4
−,7
the applications of 64Cu and 99mTc as targeted radiopharma-
ceuticals generally require the use of bifunctional chelates
(BFC) designed to selectively bind the radionuclide and to be
covalently linked to a bio-targeting vector such as an antibody,
a peptide or a protein. The ideal BFC should form thermo-
dynamically stable and kinetically inert complexes to prevent
any ligand exchange reactions or hydrolysis in vivo. The com-
plexation should be eﬃcient and rapid at room temperature
and at low concentration, at a pH suitable for biological
applications.
Among the possible ligands for 64Cu and 99mTc complexa-
tion, hydrophilic phosphonated ligands have proved to be
eﬃcient chelating agents.8–16 With phosphonated ligands, the
thermodynamic stability constants of the Cu(II) complexes are
notably higher than those of their acetate analogues.17
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Our eﬀorts to design new chelate systems for subsequent
uses in copper-64 PET imaging led us to the synthesis of the
tetra-phosphonated ligand L1 (Scheme 1), a very eﬀective and
selective Cu(II) chelating agent (log KCuL = 22.7).
11,12 We have
also shown that L1 can be derivatized into an activated phos-
phonated bifunctional chelate L* (Scheme 1) which can be
coupled to small peptides or large antibodies.18
In order to fully understand the coordination chemistry of
phosphonated chelates, we have designed a series of three new
ligands bearing two (L2) or three (L3, L4) phosphonate func-
tions on a pyridine framework (Scheme 1). The synthesis of
these ligands is reported here, together with their complexa-
tion properties towards d elements such as Cu(II), Ni(II), Zn(II)
(for ligands L2, L3, L4), and Co(II) ions (for ligand L2).
Finally the potential of such chelates for 99mTc imaging of
mice will be presented for ligands L1 and L2 and for a L*
labeled monoclonal antibody directed toward breast cancer.
Results and discussion
Synthesis of the ligands
Scheme 2 presents the diﬀerent synthetic protocols used for
the synthesis of the ligands L2 to L4. L2 was obtained according
to two diﬀerent routes. The first one started from bromation of
the commercially available 2,6-dihydroxymethylpyridine 1 with
PBr3 at 0 °C, aﬀording 2,6-dibromomethylpyridine 2 (84–95%),
which is then converted into 2,6-bis(ethylaminomethyl)pyri-
dine 3 19 in 23% yield. Phosphorylation of 3 in the presence of
diethyl phosphite and 37% aqueous formaldehyde aﬀorded
the bis-phosphonated compound 4 in 69% yield. Subsequent
hydrolysis of the phosphonate groups was performed using an
excess of TMSBr, followed by methanolysis, aﬀording ligand L2
in 83% yield.
However, due to the diﬃculties encountered in the purifi-
cation of compound 3, a second approach was elaborated for
the synthesis of L2. This protocol started with the preparation
of diethyl(ethylamino)methanephosphonate 7 from ethylben-
zylamine 5 in two steps (phosphorylation and catalytic hydro-
genolysis) and with an overall 81% yield. N-alkylation reaction
of 2 with 7 resulted in the formation of the bis-phosphonated
compound 4 (24%) which led to ligand L2 after deprotection of
the phosphonate groups using an excess of TMSBr, followed
by methanolysis (83%).
The synthesis of ligand L3 was based on a mono N-alkyl-
ation of 2 with tetra-ethyl iminobis(methanephosphonate)20 to
give the bis-diethylester phosphonated intermediate 8 in 58%
yield. Subsequent N-alkylation of 8 with diethyl(ethylamino)-
methylphosphonate 7 in acetonitrile aﬀorded the tris-phos-
phonated precursor 9 (49%). Hydrolysis of phosphonate esters
to their corresponding acids in the presence of an excess of
TMSBr in CH2Cl2 gave, after methanolysis, the ligand L
3 in a
90% yield.
Finally, the formation of ligand L4 was started by the phos-
phonylation of 2,6-dibromomethylpyridine 2 with triethylphos-
phite to yield intermediate 10 (48%) which, after N-alkylation
reaction with tetra-ethyl iminobis(methanephosphonate),20
gave the tris-phosphonated derivative 11 in 32% yield. Hydro-
lysis of phosphonate groups using 6 M HCl aﬀorded the ligand
L4 in 46% yield.
Coordination chemistry of ligands L1–L4
Protonated species of ligands L1–L4. L1 to L4 constitute a
homogeneous series of chelators with varying numbers of
terminal –PO3
2− phosphonate functions ranging from 2 to 4. If
L4 is closely related to L3 (both ligands contain three phospho-
nated –PO3
2− functions), it markedly diﬀers from L3 with one
methylamino-N,N-bis(methanephosphonate) substituent being
replaced by an ethylphosphonate moiety, –CH2–PO3
2−.
Detailed interpretation of physico-chemical data on the
metallic complexes (e.g. Cu(II), Ni(II), Zn(II), Co(II)) first requires
the complete characterization of the ligand protonation
diagram, at least in the pH range in which these data have
been collected and also with respect to the targeted appli-
cation (i.e. PET and SPECT imaging). We have therefore investi-
Scheme 1 Tetra-phosphonated ligand L1, the activated BFC L*, and the bis and tris-phosphonated ligands L2, L3 and L4.
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gated the acido-basic properties of ligands L1–L4 in the pH
range 2.0–11.5 by various techniques. First, potentiometric
titrations of ∼2 mM solutions of L1–L4 followed by statistical
processing of the data21,22 first yielded six, four, five and four
protonation constants, respectively (Table 1). Importantly,
some of the protonation constants were diﬃcult to determine
with a good accuracy in view of their extremely low values
(log KH ≪ 2).23,24 A typical example of potentiometric titrations
with the corresponding speciation diagram obtained after pro-
cessing the data is reported for L2 in Fig. 1.
The most basic protonation constants (KLH and KLH2 for L
1–
L3 and KLH for L
4) can be attributed to the tertiary amines, in
agreement with data available in the literature for related poly-
aminomethanephosphonate analogues.25–31 The following pro-
tonation constants are associated with the first protonation
constants of each of the phosphonate –PO3
2− units (i.e. RPO3
2−
+ H+ ↔ RPO3H
−), while the logarithmic values of the second
protonation constants of the protonated phosphonate groups
(RPO3H
− + H+ ↔ RPO3H2) as well as the pKa of the pyridine
Scheme 2 Synthetic protocols for the preparation of ligands L2 to L4. (i) PBr3, 0 °C, DMF, 84–95%. (ii) EtNH2, MeCN, reﬂux to r.t., 23%. (iii) HPO-
(OEt)2, 0 °C, (CH2O)n (37% in H2O), r.t. to reﬂux for 4, 69%; 0 °C to reﬂux for 6, 83%. (iv) TMSBr, CH2Cl2, r.t., then MeOH, 83% for L
2; 90% for L3. (v)
H2, Pd/C, EtOH, r.t., 98%. (vi) K2CO3, MeCN, 50 °C, 24%. (vii) HN(CH2PO(OEt)2)2, K2CO3, MeCN, 70 °C, 58% for 9; 32% for 12. (viii) 7, K2CO3, MeCN,
70 °C, 49%. (ix) P(OEt)3, 135 °C, 48%. (x) 6M HCl, reﬂux, 46%.
Table 1 Protonation constants (logarithmic KHn values) of ligands L
1–L4
in watera
Equilibrium
log KHn (3σ)
L1 b,c L2 b L3 b L4 b
Ln þ Hþ! 
KH1
LH1m 11.21(2)d 10.46(2)d 11.04(1)d 11.8(2)d
11.1(2)e
LH1n þ Hþ ! 
KH2
LH2m2 10.29(2)
d 10.07(3)d 10.4(1)d 8.3(3)d
10.71(3)e 9.94(3)e 10.8(4)e 7.9(3)e
LH2n2 þ Hþ ! 
KH3
LH3m3 8.04(4)
d 6.56(4)d 6.9(2)d 6.5(5)d
8.5(2)e 6.8(2)e
LH3n3 þ Hþ ! 
KH4
LH4m4 6.49(6)
d 4.52(5)d 5.7(3)d 5.1(6)d
7.0(3)e 5.37(4)e
LH4n4 þ Hþ ! 
KH5
LH5m5 5.53(8)
d — 4.5(3)d —
LH5n5 þ Hþ ! 
KH6
LH6m6 4.19(9)
d — — —
a Solvent: H2O; I = 0.1 M (NaClO4); T = 25.0 ± 0.2 °C.
b m = 8, 4 and 6
respectively for L1, for L2 and for L3 and L4. c According to ref 11.
d Potentiometry. e Absorption spectroscopy vs. pH. KHn = [LH
(n−
n ]/[H
+]
[LH(n−(n−1)]. The uncertainties (3σ) in the log K
H values correspond to the
added standard deviations (σ) in the cumulative constants. All other
protonation constants have been assumed to be <2.
Organic & Biomolecular Chemistry Paper
This journal is © The Royal Society of Chemistry 2014 Org. Biomol. Chem., 2014, 12, 9601–9620 | 9603
were estimated to be ≪2. If the average basicity of the phos-
phonate groups does not significantly vary along the L1–L3
series within experimental errors (log KHav = 6.06 for L
1, log KHav =
5.51 for L2 and log KHav = 5.7 for L
3), it is increased for L4
(log KHav = 6.63 for L
4) which is lacking one secondary amine.
This feature reflects inter-arm hydrogen bond interactions that
might exist between the protonated ammonium of one methyl-
amino-N,N-bis(methanephosphonate) moiety and the amine of
the adjacent one.
To assess the spectrophotometric properties of the polyami-
nophosphonate ligands L1–L4 and of their protonated species
and to confirm the pKa values determined by the pHmetric
method, we also performed spectrophotometric titrations
(200 nm < λ < 500 nm) of the free ligands as a function of pH.
As a typical example, the case of L3 is presented in Fig. 2.
Regardless of the nature of the ligand, the pyridine constitutes
the main chromophore unit and a structured absorption band
centered at ∼260–270 nm (ε ∼ 3 × 103 M−1 cm−1), which can be
ascribed to its π–π* transitions,32 was observed. Even though
the pyridine nitrogen cannot be protonated in the pH range
considered, marked spectral variations (hyperchromic shifts)
were measured which can be explained by non-covalent inter-
actions (hydrogen bonding) between the protonated side arms
and the pyridine ionizable site. Generally speaking, the most
important variations were observed when the secondary
amines are protonated (i.e. a five membered ring can be
formed upon protonation of the amine and subsequent hydro-
gen bonding with Npyr). The statistical processing
33–35 of the
absorption and pH data allowed us to substantiate some of the
protonation constants which were previously determined by
the potentiometric method (Table 1). These protolytic data
confirm that L1–L4 constitute intricate systems in terms of pro-
tolysis and strongly suggest the occurrence of hydrogen bond
networks between the pyridinyl unit and the side arms of the
ligands.
Characterization of the cupric complexes with L1–L4. The
stoichiometries of the cupric complexes formed with ligands
L1–L4 have been assessed by electrospray mass spectrometry
(ESI-MS) in the positive mode. ESI-MS mass spectra were
recorded for aqueous solutions containing equimolar concen-
trations of Cu(II) and the ligand (see Fig. 3 for L1). Regardless
of the nature of the ligand, monocupric monochelates were
systematically detected which strongly suggests that the
ligands considered in this work display appropriate denticity
and pre-organization to fulfill the stereochemical requirements
of the Cu(II) ion. The ionization of the cupric complexes was
Fig. 1 (a) Potentiometric titration curve of ligand L2 and (b) distribution
diagrams of the protonated species of the free ligand L2. Solvent: water;
I = 0.1 M (NaClO4); T = 25.0(2) °C; [L
2]tot = 2.44 × 10
−3 M; 2.47 < pH <
11.85.
Fig. 2 (a) Absorption spectrophotometric titration of L3 as a function of
pH and (b) variation of the absorbance at 256 nm vs. pH. Solvent: H2O;
T = 25.0(2) °C; I = 0.1 M (NaClO4); l = 1 cm; [L
3]tot = 2.29 × 10
−4 M.
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mainly obtained by the addition of protons and sodium ions.
Similar results were obtained with Zn(II) and Ni(II). The
pseudo-molecular ions of the diﬀerent species observed are
collected in Table S1 (ESI†) and are in good agreement with
the simulated mono-isotopic masses.
Stability of the Cu(II) complexes with L1–L4. Similarly to the
free ligands, potentiometric (Fig. S1, ESI†) and absorption vs.
pH (Fig. 4) titrations have been carried out to evaluate the
stability constants of the cupric complexes with ligands L1–L4.
Fig. S1 (ESI†) first displays the potentiometric data of aqueous
solutions containing nearly equimolar concentrations of Cu(II)
and of the ligand. These pHmetric data have been statistically
processed21 and the corresponding stability and protonation
constants of the Cu(II) complexes are shown in Table 2. Simi-
larly to most of the polyaminomethanephosphonated chela-
tors described so far, ligands L1–L4 basically form monocupric
monochelates. This binding feature is confirmed by the mass
spectrometric data conducted on L1–L4 series (Table S1, ESI†).
On the other hand, L1–L4 form Cu(II) complexes whose high
stability constants are comparable, for instance, to EDTPA (log
KCuEDTPA = 23.2)
36,37 and are much higher than that of
N-methylamino-N,N-bis(methylenephosphonic acid)38,39 which
constitutes the side arm model of L1, L3 and L4. Furthermore,
the substitution of the carboxylate functions of the (2,6-bis[bis-
((carboxymethyl)amino)methyl]pyridine25 chelator (log KCuL =
15.69) by phosphonic units (L1) stabilizes considerably the
corresponding cupric complexes. Interestingly, L1 forms more
stable Cu(II) complexes (log KCuL1 = 22.71(7)) than its closely
related analogues L2–L4. Indeed, the lack of one (L3, L4) or two
(L2) phosphonic units is reflected by a destabilization of the
Cu(II) complexes of about 3 orders of magnitude (log KCuL2 =
19.5(9), log KCuL3 = 19.1(3), log KCuL4 = 19.3(6)). These data
clearly demonstrate the importance of the four terminal phos-
phonate units of L1 for the binding strength with Cu(II).
Regarding the protonation properties of the cupric com-
plexes with L1–L4, it is noteworthy that the CuL1 species is able
to be successively protonated four times under our experi-
mental conditions, while CuL3 can lead to three protonated
species. Only two protonations were measured for the Cu(II)
complexes with both L2 and L4 (Table 2). The protonation sites
of the cupric complexes most likely correspond to phospho-
Fig. 4 Absorption vs. pH titrations of the cupric complexes formed
with (a) L2 and (b) L3. Solvent: H2O; I = 0.1 M (NaClO4); T = 25.0(2) °C;
l = 1 cm. (a) [L2]tot = 1.39 × 10
−4 M; [Cu(II)]tot = 1.30 × 10
−4 M; (1) pH =
4.15; (2) pH = 9.19. (b) [L3]tot = [Cu(II)]tot = 1.78 × 10
−4 M; (1) pH = 2.49;
(2) pH = 11.19.
Table 2 Stability and protonation constants of the cupric complexes
formed with ligands L1–L4 a
Equilibrium
log KCuLHx (3σ)
L1 L2 L3 L4
L þ Cu ! 
KCuL
CuL 22.71(9)b 19.50(9)b 19.1(3)b 19.3(6)b
CuL þ H ! 
KCuLH
CuLH 8.24(8)b 6.30(1)b 7.8(3)b 6.1(7)b
8.20(6)c 7.7(5)c 8.5(7)c
CuLH þ H ! 
KCuLH2
CuLH2 7.15(9)
b 4.71(9)b 5.8(3)b 4.9(8)b
6.9(5)c 5.7(3)c 4.9(6)c
CuLH2 þ H ! 
KCuLH3
CuLH3 5.7(1)
b — 4.3(3)b —
CuLH3 þ H ! 
KCuLH4
CuLH4 4.0(2)
b — — —
a Solvent: H2O; I = 0.1 M; T = 25.0(2) °C)]. The uncertainties (3σ) in the
log KCuLHx values correspond to the added standard deviations (σ) in
the cumulative constants. KCuLHx = [CuLHn]/[[CuLH(n−1)][H]. Charges
have been omitted for the sake of clarity. b Potentiometry. c Absorption
vs. pH.
Fig. 3 ESI mass spectra of the cupric complexes formed with ligand L1.
Solvent: H2O; positive mode. (a) [Cu] = [L
1]tot = 4.10 × 10
−4 M.
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nate units, which implies that the secondary amines remain
firmly bound to the Cu(II) cation whatever the pH considered
in this study. The involvement of the pyridinyl nitrogen cannot
be excluded as well since the stability constant of CuL1 is by
far much higher than that of the Cu(II) complex of a closely
related analogue for which the pyridine ring has been substi-
tuted by a phenyl one (log KCuL = 15.3).
40 Other linear or cyclic
analogues also bearing a pyridine unit displayed the same
binding characteristic.41,42
Lastly, if significant diﬀerences can be measured for the
phosphonates pKas in the free ligands and in the corres-
ponding complexes, the average phosphonate basicities
measured for L1–L3 are almost unaﬀected by the Cu(II) com-
plexation (L1 log KHav = 6.06, CuL
1 log KHav = 6.27; L
2 log KHav =
5.51, CuL2 log KHav = 5.51, L
3 log KHmoy = 5.7, CuL
3 log KHav = 5.96).
This feature is in excellent agreement with the observations
made for instance for EDTPA36,37 (EDTPA log KHav = 5.59,
CuEDTPA log KHCuL = 5.57). L
4 stands in interesting contrast
since it is lacking a secondary amine unit for Cu(II) binding. It
is then proposed that a phosphonate unit is firmly bound to
Cu(II), thus influencing both the number of Cu(II) protonated
complexes and the average protonation constant of the remain-
ing phosphonates (L4 log KHav = 6.63, CuL
4 log KHav = 5.5). The
distribution diagrams of the cupric complexes as a function of
pH were calculated and are available in the ESI† (Fig. S2).
Fig. 4 portrays the absorption spectral variation induced by
Cu(II) complexation as a function of the pH of the solution
containing L2 and L3 (Fig. S6–S9, ESI†). In addition to the pyri-
dine-centered π–π* transitions at ∼260 nm, the cupric com-
plexes with polyaminophosphonated ligands display
informative spectroscopic probes such as intense N→Cu(II)
charge transfer absorptions43,44 as well as weaker Cu(II)-cen-
tered d–d transitions.45,46 These absorptions allowed monitor-
ing several key events such as the Cu(II) complexation by L1–L4
and the protonation of the cupric complexes and provided
information on the coordination geometry of the metal. L1–L3
are characterized by intense N→Cu(II) CT absorptions at about
300–310 nm which clearly indicate that the two secondary
amines are strongly involved in the complexation of the met-
allic ion whatever be the pH considered (2.5–11). Sub-
sequently, L4, which is lacking one secondary amine, displays
a much weaker MLCT absorption. For CuL1 (4 phosphonates)
and CuL3 (3 phosphonates), the rise in the pH induces a bath-
ochromic shift of about 40–50 nm of the N→Cu(II) CT tran-
sitions as well as the d–d absorption bands, while very weak
variations were observed for cupric complexes with L2 (2 phos-
phonates) and L4 (3 phosphonates, only one secondary N).
This shift is probably associated with the weakening of one to
two Cu–N bonds, as observed for the thiophene containing
phosphonate ligand.47 Above pH 9, no spectral variation was
observed for each of the systems. Regardless of the system con-
sidered, the binding of Cu(II) weakly influences the pyridine
π–π* transitions. The significant spectral variations experi-
enced by the tetra- (L1) and tris-phosphonated L3 ligands there-
fore likely reflect structural and geometrical modifications of
the Cu(II) coordination sphere influenced by the deprotonation
of the phosphonic units. The statistical processing33–35 of the
spectral and pHmetric data sets allowed determining the pro-
tonation constants of the Cu(II) complexes, which were found
to be in good agreement with those previously measured by
the potentiometric method (Table 2).
Selectivity of Cu(II) complexation toward other metal ions:
the case of Ni(II), Zn(II) and Co(II). Using potentiometry, it was
possible to accurately determine the stability constants
(Table 3) of the metallic complexes with the Zn(II), Ni(II) and
Co(II) cations with ligands L1–L4. Similarly to Cu(II), protonated
metal complexes were evidenced and their corresponding pro-
tonation constants are depicted in the ESI† (Table S2 and
Fig. S2 to S5). These data were compared to those available in
the literature for reference chelators such as the L1 analogue
bearing terminal carboxylates (denoted L1C in Table 3) and
DO2P (1,4,7,10-tetraazacyclododecane-1,7-bis(methanephos-
phonate)), which constitutes a golden standard and is one of
the most eﬀective Cu(II) chelators described so far.
The complexation of Cu(II) by ligands L1–L4 is selective com-
pared to that of Zn(II), Ni(II) or Co(II). This binding selectivity
also exists for other polyaminomethanephosphonate ligands
such as DO2P.12 The sequence of LM stability constants
(Table 3) is indeed in agreement with the Irving–Williams
series which defines that the classical thermodynamic order
for transition-metal complexes is Mn(II) < Fe(II) < Co(II) < Ni(II)
< Cu(II) > Zn(II).48–50
For Cu(II), the presence of four phosphonate units clearly
stabilizes the Cu(II) complexes, while small diﬀerences are
observed for the analogous ligands L2–L3. L1 is the most appro-
priate system to stabilize Cu(II) in a distorted square planar
pyramidal geometry. Due to its versatility, the presence of a
square planar geometry cannot be excluded under acidic con-
ditions where the phosphonate units are protonated. Indeed,
L1 forms stable complexes for pH < 4 and competes with DO2P
under these experimental conditions. By contrast, L3 and L4,
both bearing three phosphonate groups, form with Ni(II) the
most stable complexes. This would indicate that these two
ligands better fulfill the stereochemical preferences of Ni(II)
(octahedral geometry) with respect to L1 or L2. L1 is seemingly
Table 3 Stability constantsa of metallic complexes (Cu(II), Zn(II), Ni(II)
and Co(II) formed with ligands L1–L4 and corresponding pMb values
log KML(3σ)
a
pM (pH 7.4)b L1 L2 L3 L4 L1C DO2P
log KCuL 22.71(7) 19.50(9) 19.1(3) 19.3(6) 15.69 28.7
pCuII 15.46 12.89 12.08 13.06 12.07 17.77c
log KNiL 16.50(3) 14.34(6) 18.2(2) 18.1(4) — —
pNiII 11.79 9.54 13.08 13.65
log KZnL 17.84(4) 11.99(6) 17.2(2) 12.1(3) 15.84 21.2
pZnII 12.37 8.93 11.89 8.44 13.68 11.73
log KCoL 16.50(9) 13.9(1) nd nd — —
pCoII 11.22 8.86
a LþM ! 
KML
ML, KML = [ML]/[M][L].
b pM = −log[M]free calculated for
[M]tot = 10
−6 M and [L]tot = 10
−5 M at pH 7.4. Solvent: H2O; I = 0.1 M; T
= 25,0 °C. c pM values calculated without the protonation constants of
the metal complexes which have not been reported. nd = not
determined.
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not an ideal binding platform for metal ions of strict coordi-
nation geometry such as Ni(II). The main diﬀerences between
Cu(II) and Ni(II)/Zn(II) can therefore be explained by the stereo-
chemical preferences of these two cations.
To further discuss the complexation properties of L1–L4, we
calculated the pM values51 for each of these systems (Table 3).
Fig. 5a depicts the pM values calculated for L1 with Cu(II),
Zn(II), Ni(II) and Co(II) and demonstrates the high selectivity of
L1 for Cu(II) over a wide range of pH (2–12) (for L2–L4, see
Fig. S12 to S14, ESI†). The same feature is observed for ligands
L2–L4. On the other hand, Fig. 5b illustrates the pCuII values of
L1–L4 compared to those of DO2P and EDTPA chosen as refer-
ences in this study. Ligands L1–L4 display good aﬃnity for Cu(II)
and the pCuII values systematically increases with the pH of the
solution until pH ∼ 7–8 (competition under basic conditions
with hydrolysis of the metals). The stability sequence at physio-
logical pH is as follows: DO2P > L1 > EDTPA-L4 > L2 > L3. Inter-
estingly, L1 is among the most powerful Cu(II) chelator under
acidic conditions and competes with DO2P which is ineﬃcient
at pH < 4. In the pH range from 6 to 12, DO2P can be con-
sidered as the most eﬃcient Cu(II) chelator with respect to
L1–L4. This study demonstrates that the presence of at least
three phosphonated binding units is required to firmly bind
Cu(II) above pH 7. Increasing the number of phosphonated
coordinating groups clearly favors the Cu(II) complexation under
acidic conditions, which is of fundamental importance when
anticipating PET imaging on cancer cells for instance.
Electrochemical properties. The electrochemical properties
of a potential 64Cu chelate are among the most important
physico-chemical parameters to be considered for PET
imaging applications. In vivo reduction of the cupric complex
by biological reducing agents might indeed lead to unstable
and extremely labile copper(I) species. Upon reduction, the
64Cu(I) cation may undergo dissociation (by solvolysis, acidoly-
sis or ligand exchange processes) and the radioactive cation
could then be widespread in the body with subsequent loss of
the selectivity with respect to the target to be imaged and
appearance of adverse health eﬀects. It was then of importance
to establish the electrochemical properties of the Cu(II) chelate
with L1–L4 and to assess if they might be subjected to easy
reduction by biological reducing agents (i.e. E1/2 should be
≥−0.4 V per NHE). Cyclic voltamperograms (CV) were recorded
in water (0.1 M NaClO4) at diﬀerent pH values (3.7 ≤ pH ≤ 11,
Fig. S10 and S11, ESI†). Fig. S10 (ESI†) displays the CVs
measured for ∼mM solutions of CuLi (i = 1–4) at pH 3.7.
Under these experimental conditions, the less stable cupric
complexes mainly co-exist under negatively multicharged
states ([CuL1H3]
3−/[CuL1H4]
2−; [CuL2H]−/[CuL2H2]
0; [CuL3H2]
2−/
[CuL3H3]
−; [CuL4H2]
2−). For the sake of clarity, the CV of a mM
solution of Cu(ClO4)2 has also been recorded. Whatever the
system considered, we systematically observed the presence of
two irreversible cathodic signals as well as a so-called anodic
stripping peak (at ∼0.1 V and caused by redissolution of met-
allic copper) that is a clear signature of the formation of Cu0.52
The presence of Cu0 was further assessed by the formation of a
thin orange deposit on the surface of the glassy carbon elec-
trode. For L3 and L4, an additional cathodic peak at −0.12 V
seemingly corresponds to reduction of free copper(II). The two
cathodic peaks (Table 4) may be ascribed to the Cu2+Li→Cu+Li
and Cu+Li→Cu0 + Li (i = 1–4) reduction steps, respectively. The
presence of the redissolution peak at ∼0.1 V indeed suggests
that the electrogenerated Cu(I) and Cu(0) complexes derived
from ligands L1–L4 are unstable and dissociate. This feature is
confirmed by the irreversibility of the two cathodic peaks
whose intensity and potential values are markedly influenced
by the potential scanning rate.53,54 In addition, these electro-
chemical processes are not governed by diﬀusion. Taken
together, these data support a chemical reaction (dissociation
of the cuprous complexes, denoted C) that precedes an elec-
tron transfer (reduction of the cupric complexes, denoted E,
EC mechanism).55
When the pH was raised (pH > 5.6), the CV pattern is mark-
edly simplified for all systems considered with the formation
of a quasi-reversible system whose redox potential is shifted at
more positive values. The quasi-reversibility is supported by
the ipa/ipc intensity ratios which are close to 1 and by the ΔE
values (Table 5). The quasi-reversibility persists even after
several scans whatever the potential scanning rate, meaning
that the electrogenerated Cu(I) complexes are stable enough on
Fig. 5 (a) Variation of the pM values (M = CuII, ZnII, NiII and CoII) as a
function of pH for ligand L1 and (b) variation of the pCuII values for L1–
L4 compared to those of DO2P and EDTPA. Solvent: H2O; I = 0.1 M; T =
25.0(2) °C; pM = −log[MII]free or −log[MIII]free, [L]tot = 10−5 M and [MII]tot
or [MIII]tot = 10
−6 M.
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the CV timescale. These features are in good agreement with
the stronger stabilities of the cuprous complexes which
prevent Cu(II) and Cu(I) dissociation and thereby Cu0 for-
mation (the anodic redissolution peak is suppressed under
basic conditions).
To further assess the electrochemical stability of the cupric
complexes with L1–L4, we tested the resistance of these com-
plexes toward biological reductants such as ascorbic acid
(DHA/Asc; E0 = +0.054 V per NHE at pH 7.0; intracellular con-
centration from 10 000 to 20 000 µM) or NADPH (NAD(P)/
NAD(P)H; E0 = −0.32 V per NHE at pH 7; intracellular concen-
tration from 200 to 500 µM) at pH 7.4 (tris buﬀer). The N–Cu(II)
CT absorptions constituted a valuable probe to evaluate the
reductant-decomposition of the cupric complexes (Fig. 6). As
expected, the CuLi complexes (i = 1–4) are more stable with
respect to ascorbic acid (E0 = +0.054 V per NHE) than to
NAD(P)H (E0 = −0.32 V per NHE). On the other hand, CuL2
and to a lesser extent CuL1 appear to be the most resistant
cupric complexes in the presence of NADPH, in agreement
with their electrochemical properties (Fig. S10 and S11, ESI†).
Formation and dissociation mechanisms of the cupric
complexes with L1–L4
Formation kinetics. If a high thermodynamic stability of the
Cu(II) complex with a ligand is a prerequisite for its use in
64Cu PET imaging, it may also be associated with very slow
kinetics for the formation of the complex, as observed for
some cross bridged cyclen derivatives,8 and a fast complexa-
tion may be preferred to avoid a necessary heating step. The
formation kinetic studies of the Cu(II) complexes with L1–L4
were first carried out using stopped flow spectrophotometry at
pH ∼ 2. The complexes [CuL1H4]2−, [CuL2H2]0, [CuL3H3]−, and
[CuL4H2]
2− are the major species at pH 2.0, while Cu2+ is the
predominant free copper(II) species under these experimental
conditions of acidity (KCu(OH)+ = 10
−6.29 and KCu(OH)2 =
10−13.1).56 We have chosen to monitor the formation kinetics
under pseudo-first order conditions ([Cu2+]tot > 10 × [L]tot) at
λ > 300 nm (i.e. N→Cu CT absorptions), which corresponds to
the largest spectrophotometric amplitudes between the
absorptions of the reactants (Cu2+ + L1–L4) and of the product
CuLi (i = 1–4). Whatever the system considered, the absorbance
always experienced an exponential growth versus time indicat-
ing a first order kinetics (v = −d[L]/dt = kobs[L]) with respect to
the ligand. The kinetic recordings revealed single rate limiting
steps in the millisecond to second time spans and, impor-
tantly, spectral amplitudes were lost during the mixing time
(∼3 ms) of the stopped-flow device. The absorbances at the
end of the rate limiting steps satisfactorily correspond to the
expected values for the CuLi complexes at pH ∼ 2, signifying
the absence of any slowest steps.
Formation kinetics of metal complexes and, in this particu-
lar case, of copper(II) complexes44,57,58 with a wide variety of
Table 4 Electrochemical parameters measured for the Cu(II) complexes
with L1–L4 in water at pH 3.7
Complex
1st reduction
peak (Pc1)
2nd reduction
peak (Pc2)
Cu0
redissolution
peak
Epc1
(V per
SCE)
ipc1
(μA)
Epc2
(V per
SCE)
ipc2
(μA)
Ire
(μA)
Ere
(V per
SCE)
CuL1 −0.51 −66 −1.1 −286 144 0.17
CuL2 −0.26 −45 −1.0 −136 121 0.12
CuL3 −0.39 −112 −1.13 −389 326 0.19
CuL4 −0.55 −206 −1.06 −213 165 0.12
Solvent: H2O; I = 0.1 M (NaClO4); T = 25.0(2) °C; v = 200 mV s
−1.
Reference = Ag/AgCl.
Table 5 Electrochemical parameters measured for the Cu(II) complexes
with L1–L4 in water at pH > 10a
Complex Epc1 (V) Epa1 (V) ipa1/ipc1
CuL1 −0.5 0.01 0.83
CuL2 −0.5 −0.26 0.54
CuL3 −0.16 0.25 1.24
CuL4 −0.07 0.29 0.94
a Solvent: H2O; I = 0.1 M (NaClO4); T = 25.0(2) °C; v = 200 mV s
−1.
Reference = Ag/AgCl.
Fig. 6 Spectrophotometric titrations of CuLi (i = 1–4) complexes with
(a) ascorbic acid and (b) NADPH. Solvent: aqueous Tris-HCl (0.05 M) at
pH 7.4, [CuLi]tot = 3 × 10
−4 M; l = 1 cm; T = 25.0(2) °C.
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ligands showed that these metal complexation processes
usually follow a dissociative Eigen–Wilkins mechanism:59,60
L Sð Þ þ M sð Þ ! 
Kos
ML sð Þ þ S ! 
kex
MLþs ð1Þ
The rate limiting step (kex) corresponds to the desolvation
of the metal in an outer-sphere complex formed in a fast pre-
equilibrium (Kos):
kf ¼ Kos  kex with kf ðM1 s1Þ; Kos ðM1Þ and kex ðs1Þ ð2Þ
Estimating the Kos
61 values for the free ligands at pH ∼ 2
and Cu2+ and assuming the reported kex value
62–64 (2 × 108 s−1
in water at 25 °C) for the desolvation of the Cu2+ cation, we
evaluated the theoretical kf values (Table 6).
The large values of kf agree well with the loss of spectral
amplitude during the mixing time of the stopped flow appar-
atus and suggest that the first steps likely correspond to the
formation of kinetic intermediates. The pseudo-first order rate
constants kobs (s
−1) of the rate-limiting step were determined
for various Cu2+ concentrations (Fig. 7). With the exception of
L4, the ordinates at the origin were found to be close to zero.
Under large excess of Cu(II), the formation of the cupric com-
plexes is indeed favored with respect to the dissociation
pathway, thus precluding reliable measurement of the dis-
sociation kinetic k−1CuL parameter. For L
1 (4 phosphonate
units) and L3 (3 phosphonate units), the dependence of kobs
on [Cu2+]tot therefore satisfactorily obeys eqn (3), while a linear
dependence was observed for L2. Strikingly, no variation of the
kobs values with [Cu
2+]tot was observed for L
4:
kobs¼
kCuL K ½CuL* ½Cu2þtot
1þK ½CuL* ½Cu2þtot
ð3Þ
These features can be rationalized by considering the first
step (lost during the mixing time) as a very fast pre-equili-
brium (formation of a kinetic Cu(II) intermediate [CuL]*) fol-
lowed by a rate limiting rearrangement (formation of the final
complex CuL) as described by eqn (4) and (5) (i.e. as described
above, the monomolecular rate constant could not be accu-
rately determined under these experimental conditions):
L*þ Cu2þ! 
K ½CuL*; fast
CuL½ * ð4Þ
CuL½ * *) 
kCuL
k1CuL
CuL ð5Þ
The kinetic behaviors for L2 and L4 correspond to extreme
situations depicted in eqn (6) and (7) that intimately depend
on the very low (L2) or very high (L4) stabilities of the kinetic
intermediate [CuL]*, respectively.
For L4: if K ½CuL*  ½Cu2þtot  1 then kobs ¼ k½CuL ð6Þ
For L2: if K ½CuL*  ½Cu2þtot  1 then
kobs ¼ k½CuL K ½CuL* ½Cu2þtot
ð7Þ
In the case of an intermediate complex such as [CuL4]*,
whose structure is close to the product, the kobs values are
independent of [Cu2+]tot. The ligand L
4 indeed displays three
phosphonated units and only one secondary amine. The stron-
ger implication of the binding units within the kinetic inter-
mediate complex [CuL4]* (i.e. the stability constant of the
kinetic intermediate is expected to be close to that of the final
product) would explain the diﬀerence with respect to [CuL1]*
(log K[CuL1]* = 2.1(2)/k[CuL1] = 59(9) s
−1) and [CuL3]* (log K[CuL3]*
= 1.5(2)/k[CuL3] = 220(40) s
−1) for which a saturation kinetics
has been evidenced (i.e. a much larger diﬀerence between the
kinetic intermediate and the final complex is anticipated). In
the case of the L2 system (bearing 2 phosphonate units), the
much lower stabilities of the intermediate complexes [CuL2]*
compared to that of [CuL1]* (4 phosphonate units) and [CuL3]*
(3 phosphonate units) enlighten their peculiar formation kine-
tics. Therefore, only the product k[CuL] × K[CuL]* could be evalu-
ated (Table 7). The forward (k[CuL]) rate constants as well as the
stability constants of the kinetic intermediates are collected in
Table 7. The stability constants of [CuL2]* and [CuL4]* were
not determined under our experimental conditions and their
values have been estimated to be >101.5 M−1 for [CuL2]* and
∼log K[CuL4]* for [CuL4]*.
Our kinetic data clearly demonstrated fast formation of
kinetic Cu(II) intermediates for L1–L4 followed by a rate-limit-
ing rearrangement to the final more stable cupric complexes.
According to the Eigen–Wilkins principle (Table 6), the for-
Table 6 Estimated Kos, kex and kf average values for ligands L
1–L4 in
water at pH 2
Ligand Kos (M
−1) kf (M
−1 s−1)
L1H6
2− 1.14 2 × 108
L2H4 0.16 3.2 × 10
7
L3H5
− 0.43 8.6 × 107
L4H4
2− 1.14 2 × 108
Fig. 7 Variation of the pseudo-ﬁrst order rate constants kobs (s
−1) as a
function of [Cu2+]tot for the formation of the cupric complexes with L
1–
L4. Solvent: H2O; T = 25.0(2) °C; l = 1 cm; I = 0.1 M (NaClO4); [L
1]tot =
3.04 × 10−4 M, [L2]tot = 1.80 × 10
−4 M, [L3]tot = 2.06 × 10
−4 M and [L4] tot
= 1.63 × 10−4 M.
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mation of the cupric kinetic intermediates is extremely fast
and agrees with the large amplitudes lost during the dead
time of the stopped-flow apparatus (ca. 3 ms). With the excep-
tion of L4 for which the stability constant of the kinetic inter-
mediate is assumed to be close to that of the final cupric
complex, we clearly demonstrated that the stability of the
kinetic intermediate and the monomolecular rearrangement
rate are intimately dependent on the number of phosphonate
units. The stepwise increase of the number of phosphonates
for L1–L3 stabilizes the kinetic intermediate and slows down
the rearrangement process. The k[CuL] × K[CuL]* values are in
the same order of magnitude which suggests that the CuLi (i =
1–3) complexes are likely sharing similar rearrangement fea-
tures (the final coordination of the nitrogen binding units).
Dissociation kinetics of the Cu(II) complexes. In addition to
a high stability, 64Cu chelators have to also display strong
kinetic inertness with respect to demetallation in the main
biological compartments (e.g. blood plasma at pH 7.35–7.45,
bile at pH 7.4–7.7, etc.). This demetallation reaction can be
even more favored in the more acidic compartments (gastric
juices, pH 1.2–3) or by exchange processes with other specific
endogenous Cu(II) chelators (e.g. Cu(II) transporters in the
blood plasma and liver: metallothionein, ceruloplasmin, trans-
cuprein or albumin).65 For all these reasons, slow dissociation
or exchange reaction is an essential property for a 64Cu chela-
tor in order to prevent adverse eﬀects in the body and also
deterioration in image quality. The proton-assisted dis-
sociation kinetics of the cupric complexes formed with L1–L4
has therefore been carried out using a stopped-flow absorption
spectrophotometer and monitored at the maximum of the
N→Cu(II) CT transitions.
The global decomplexation reactions, under acidic con-
ditions, can be written as follows:
CuL1
 6 þ 6Hþ ! L1H6
 2 þ Cu2þ
CuL2
 2 þ 4Hþ ! L2H4
 0þ Cu2þ
CuL3
 4 þ 5Hþ ! L3H5
  þ Cu2þ
CuL4
 4 þ 4Hþ ! L4H4
 2 þ Cu2þ
ð8Þ
During the dissociation kinetics of the Cu(II) complexes, we
observed a large amplitude loss of the LMCT absorbance
during the dead time of the stopped flow device (∼3 ms). This
suggests the existence of very fast steps that are not accessible
under our experimental conditions. The LMCT absorbance was
monitored versus time for several concentrations of perchloric
acid in the range 0.02 M < [H+] < 0.5 M for CuL1 and 0.04 M <
[H+] < 1 M for CuLi (i = 2–4). In all cases, the absorbance vari-
ation could be fitted with a single exponential function
(Fig. 8a) and thereby demonstrates that the rate-limiting dis-
sociation step is first order with respect to the cupric com-
plexes. The corresponding pseudo first-order rate constants
are reported in Fig. 8b. The dissociation kinetics of CuL4 (i.e.
L4 lacks a secondary amine with respect to L3) was too fast to
be accurately measured under our experimental conditions.
The pseudo-first-order dissociation rate constants of the
Cu(II) complexes linearly vary with [H+] with a non-zero intercept
at the origin. These kinetic data can be described by the follow-
ing relationship, with kH (M
−1 s−1) being the bimolecular acido-
lysis rate constant and kd (s
−1) the monomolecular solvolysis
rate constant of the complexes with L1–L4 (eqn (9); Table 8):
kobs ¼ kH  ½Hþtot þ kd ð9Þ
Our results show a significant decrease in the N→Cu(II) CT
absorbance that is in agreement with the fast dissociation of
Table 7 Kinetic and thermodynamic constants related to the formation
of the cupric complexes with ligands L1–L4 at pH 2a
Complexes log K[CuL]
b log K[CuL]*
k[CuL] (±σ)
(M−1 s−1)
k[CuL] × K[CuL]*
(±σ) (×103 M−1 s−1)
CuL1 6.04b 2.1(2)c 59(9)c 7.43d
CuL2 2.29b ≪1.5d ≫220c 3.32(5)c
CuL3 2.46b 1.5(2)c 220(40)c 6.96d
CuL4 2.6b ∼log K[CuL4] 4.23(2)c nd
a Solvent: H2O; T = 25.0(2) °C; l = 1 cm; I = 0.1 M (NaClO4).
b Apparent
stability constant recalculated from data available in Tables 1 and 2.
cMeasured values. d Estimated or calculated values.
Fig. 8 (a) Variation of the absorbance at 312 nm for the proton-assisted
dissociation of CuL1. [CuL1]tot = 7 × 10
−5 M; [H+]tot = 5 × 10
−3 M. Initial
pH = 10. (b) Variation of the pseudo-ﬁrst order rate constants kobs (s
−1)
as a function of [H+]tot for the proton-triggered dissociation of the
cupric complexes with L1–L3. Solvent: H2O; T = 25.0(2) °C; l = 1 cm; I =
0.1 M (NaClO4); [CuL
1]tot = 7 × 10
−5 M, [CuL2]tot = 5.67 × 10
−5 M and
[CuL3]tot = 6.84 × 10
−5 M. The cupric complexes have been initially pre-
pared at pH ∼ 10.
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the Cu–phosphonate bonds and suggests a rate-limiting step
related to the protonation of the bound secondary amines and
to the subsequent dissociation of the N–Cu coordination
bonds. The large signal amplitude lost during the dead time
of the stopped-flow apparatus indeed corresponds to succes-
sive fast protonation equilibria prior to the limiting dis-
sociation step. As an example of the L1 system, the protonated
species [CuL1H4]
2− (i.e. the 4 phosphonate units are proto-
nated) might correspond to the kinetic intermediate originat-
ing from fast protonation steps. The absorption electronic
spectra of the [CuL1H2]
4−, [CuL1H3]
3− and [CuL1H4]
2− species
are similar and indicate that the involved protonations do not
alter the chromophore (i.e. LMCT). As an example, the
suggested mechanism is shown schematically in Fig. 9 for
CuL1. The limiting step corresponds to the protonation of an
amino function and to the concomitant cleavage of the corres-
ponding N–Cu bond to aﬀord the unstable intermediate I1
which then dissociates very rapidly by the attack of another
proton. It is noteworthy that the I1 kinetic intermediate has a
putative structure similar to that which can be anticipated for
the CuL4 system structure in excellent agreement with its very
fast dissociation under very acidic conditions.
As far as acidolysis or solvolysis is concerned, the most
inert system unexpectedly corresponds to the cupric complexes
with L2 that possesses fewer phosphonate units (Fig. 10). For
the acidolysis pathway, increasing the number of phosphonate
groups may assist the proton transfer to the nitrogen atoms
(relay mechanism) and hence increase the dissociation rate kH.
The number of phosphonate units (Fig. 10) indeed strongly
influences the kinetic inertness of the I1 intermediate complex
that is subjected to a dissociation rate limiting step. For the
solvolysis pathway, charge repulsion between the non-bound
and negatively charged phosphonates as well as structural con-
straints applied to the cupric intermediate complexes may
explain this peculiar kinetic behavior.
Labeling and characterization of MTn12 antibody with L*
Tenascin-C (TNC) is a glycoprotein highly expressed during
embryogenesis but largely restricted or absent in healthy adult
tissues.66 Its expression is regained in several pathological
situations including many human cancer types.67 Many anti-
bodies against TNC have been identified and developed, and
some of them are currently used in preclinical or clinical
trials.68 The MTn12 antibody is a rat monoclonal antibody of
the IgG1 type with both specificity and relatively high aﬃnity
for murine tenascin-C.69 Therefore this antibody was a good
candidate to test novel labeling strategies in preclinical murine
models of cancer, including breast cancer or insulinoma
models,70 in which tenascin-C is known to be highly expressed
in vivo.
Prior to labeling, a MALDI/MS analysis was carried out on
MTn12 which was found to have a molecular mass of
148 100 Da. The L* labeled MTn12 (L*-MTn12) was also ana-
lyzed by MALDI/MS (Fig. 11). The mass spectrum shows a shift
of the monocharged peak [M + H]+ to the higher masses due
to the addition of the BFC. At the maximum, this shift is of
about 1000 Da which would roughly correspond to two ligands
per antibody.
Immunofluorescence staining
In order to verify that the labeling protocol did not perturb the
immunoaﬃnity of the MTn12 antibody towards tenascin-C,
immunofluorescence staining experiments were performed in
which MTn12 and L*-MTn12 were incubated on insulinoma
tissue sections from RIP1-Tag2 mice.70,71 The presence of the
MTn12 antibody was then revealed by staining with an anti-rat
secondary antibody labeled with a Cyanine3 dye (Cy3).
A control experiment was performed in which no MTn12 was
added prior to the addition of the secondary antibody. As can
Table 8 Kinetic constants related to the proton-assisted dissociation of
the cupric complexes with ligands L1–L3a
Complex kH (×10
2 M−1 s−1) (± σ) kd (s
−1) (± σ)
CuL1 3.0(2) 81(4)
CuL2 1.11(1) 0.3(2)
CuL3 2.8(3) 45(14)
a Solvent: H2O; T = 25.0(2) °C; I = 0.1 M (NaClO4).
Fig. 9 Suggested proton-promoted dissociation mechanism of CuL1.
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be seen in Fig. 12, both MTn12 and its L* labeled version
could be detected in tumors of the pancreata sections, con-
firming that the labeling with L* did not aﬀect the immu-
noaﬃnity of MTn12.
SPECT/CT imaging studies with 99mTc complexes of ligands
L1, L2 and L*-MTn12
The chelating aﬃnity of ligands L1 and L2 towards 99mTc was
first checked using radiochromatography experiments consist-
ing in the comparison of the retention factors of 99mTc in the
presence and absence of the ligands. The radiochemical purity
for L1 and L2 was above 95%. The biodistribution of the com-
plexes formed with the two ligands was then analyzed by
SPECT imaging of mice injected with the radioactive com-
plexes. As can be seen in Fig. 13, the biodistribution profile
was very diﬀerent in each case.
Fig. 10 Variation of the acidolysis (kH) and solvolysis (kd) rate constants
measured for CuL1, CuL2 and CuL3 complexes as a function of the
number of phosphonates.
Fig. 11 (A) MALDI-TOF MS spectra of MTn12 (upper) and L*-MTn12 (lower). (B) Zoom of the m/z region from 142 000 to 155 000 showing the 1000
units shift in mass due to the added chelate.
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In the case of L1, the complex rapidly accumulates in the
kidneys after 5 minutes, and an important part of it can be
found in the bladder after 2 h. But it could be noticed that a
large part of the complex accumulated in bone tissues of the
knees, shoulders, the nose and the spine, as can be observed
after 4 h (Fig. 13). This behavior has already been observed for
other phosphonate based 99mTc complexes and is clearly
related with the phosphonate contents of the chelate.15,72 In
contrast, 7 minutes after injection of the L2 complex, a large
part of the complex could be found in the kidneys, and it was
transferred to the bladder after 1 h 10 min. After 4 h, radio-
labeled L2 could still be found in the kidneys and the spleen,
but also at the joints (knees and shoulders). It is surmised that
the rapid clearance of the complex of L2 may be related to the
presence of the two ethyl chains replacing two phosphonate
moieties and giving the complex a more lipophilic character.
Finally, the targeting eﬃciency of 99mTc-L*-MTn12 was
questioned by injecting it into a transgenic mouse with breast
cancer (a transgenic MMTV-NeuNT breast cancer mouse).73 As
can be seen in Fig. 14, the radiolabeling was very rapidly
found to accumulate in the liver followed by its excretion
through the bladder. The same distribution could be observed
after 5 h 07 min and 22 h 50 min.
In living mice, the rapid accumulation of the 99mTc-L*-
MTn12 antibody in the liver may be explained by the fact that
IgG containing a Fc (constant domain) domain is known to be
primarily endocytosed and degraded by liver parenchymal,
endothelial and Kupﬀer cells thanks to the specific expression
of the cognate receptors by these liver cell types.74
Conclusion
We have synthesized and characterized a new family of ligands
based on a pyridine scaﬀold functionalized with varying
numbers of phosphonated functions. The physico-chemical
properties of the ligands and their complexes have been
studied. Whatever the ligands, monometallic species were
observed by mass spectrometry for equimolar solutions of
metal and ligands. All the ligands showed a conventional
trend for complexation, following the Irving–Williams order of
aﬃnity.48–50 Nevertheless, ligands L1 and L2 displayed a very
good selectivity for Cu(II) (Δlog KML > 5) with pCuII values com-
patible with their potential use for 64Cu PET imaging. Interest-
ingly, the loss of a single phosphonate function compared to
the tetra-phosphonated ligand L1 immediately resulted in a
drastic loss of aﬃnity towards Cu(II) of three orders of magni-
tude. More surprising, the loss of a second phosphonate func-
tion to lead to L2 did not have such an impact on the aﬃnity.
These results remain poorly understood in the absence of a
clear definition of the coordination polyhedra oﬀered by the
ligands. Unfortunately, the presence of numerous protonated
forms of the Cu(II) complexes in water highly complicates the
interpretations of possible EPR measurements,12,47 and was
not informative in our hands. Full electrochemical characteri-
zation of the cupric complexes was performed, here again
showing the availability of the complexes of L1 and L2 to resist
biological reduction, a necessary prerequisite for their use
in vivo. A thorough investigation of the formation and dis-
sociation kinetics of the cupric complexes evidenced very rapid
formations, while the proton assisted dissociations were pro-
portional to the number of phosphonate units.
Fig. 12 Immunoﬂuorescence staining on RIP1-Tag2 insulinoma tissue
sections using L*-MTn12 (a), MTn12 (b) or no secondary antibody as a
control (c). Antibody binding was revealed with a Cy3-coupled anti-rat
secondary antibody (red) and cell nuclei were stained with DAPI (blue).
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Considering their potential interest for in vivo imaging, the
ability of ligands L1 and L2 to coordinate 99mTc were studied
by radiochromatography and by SPECT/CT imaging on healthy
mice, showing a preferred fixation of the 99mTcL1 complex on
bone tissues, while the complex of L2 was rapidly excreted
through the kidneys and bladder. Finally, a bifunctional
version of L1 was used to label MTn12, a rat monoclonal anti-
body directed against murine tenascin-C. Although immuno-
fluorescence staining experiments revealed unperturbed
selectivity in tumors of the pancreata, the injection of 99mTc
radiolabeled antibody into a transgenic mouse bearing a
breast primary cancer showed the antibody to be readily accu-
mulated in the liver, followed by excretion, with no specific
signal in the tumor. A possible explanation is that the constant
fragments of this IgG antibody were primarily endocytosed by
liver cells74 and our current eﬀorts are directed towards the
development of F(ab)′2 fragments of MTn12 (that lacks the
constant fragments) for their labeling and in vivo imaging.
Experimental section
Synthesis of the compounds
General methods. Column chromatography and flash
column chromatography were performed respectively on silica
(0.063–0.200 mm, Merck) and silica gel (40–63 μm, Merck).
Solvent mixtures used for TLC and flash column chromato-
graphy are reported in v/v ratios. 1H and 13C NMR spectra were
recorded on an Avance 300 spectrometer at 300 MHz for
proton frequency and 75 MHz for carbon frequency. 31P NMR
spectra (161.9 MHz) were recorded on Avance 400 apparatus
with H-decoupling. Chemical shifts are given in parts per
million, relative to the residual protic solvent peak.75 IR
spectra were recorded on a Nicolet 380 FT-IR spectrometer
(Thermo Scientific). Mass spectra (MS) and elemental analyses
were obtained by the Service Commun d’Analyse de l’UdS.
Solvents were used as received. Commercially available
reagents were used without further purification.
2,6-Bis(ethylaminomethyl)pyridine 3 19 and tetra-ethyl imino-
bis(methanephosphonate)20 were synthesized according to the
literature procedures.
2,6-Dibromomethylpyridine 2. To a solution of 2,6-dihydroxy-
methylpyridine (2.80 g, 20.1 mmol) in DMF (15 mL) was added
dropwise, at 0 °C, PBr3 (4.35 mL, 46.3 mmol). The mixture was
stirred at room temperature for 4 h and water was added
(20 mL). After extraction with Et2O (3 × 100 mL), the organic
layer was dried with Na2SO4 and the solvent was removed
under reduced pressure. 2,6-Dibromomethylpyridine 2 was
obtained as a pure white solid (4.81 g, 95%). All analyses corre-
spond to those reported in the literature.76
Tetraethyl(((pyridine-2,6-diyl-bis(methylene))-bis(ethylazane-
diyl))-bis(methylene))-bis (phosphonate) 4. Procedure 1: A
mixture of 2,6-bis(ethylaminomethyl)pyridine19 3 (170 mg,
0.88 mmol) and diethyl phosphite (243 mg, 1.76 mmol) was
cooled for 10 minutes in an ice-bath and 220 µL of form-
aldehyde (37% in water) were added slowly maintaining the
Fig. 13 Top (left) and 100° (right) SPECT/CT images of mice injected with 99mTc complexes of L1 and L2, after 4 h 16 and 4 h 30 respectively.
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temperature below 10 °C. The ice bath was removed and the
mixture was stirred at room temperature for 30 minutes and
refluxed for 3 h. The solution was concentrated under vacuum
and the crude product was purified by flash chromatography
(CH2Cl2/MeOH 100/0 to 92/8) to give compound 4 as an oil
(302 mg, 69%). 1H NMR (CDCl3, 300 MHz): δ 7.59 (t,
3JH–H =
7.7 Hz, 1H, Hpyr), 7.37 (d,
3JH–H = 7.6 Hz, 2H, Hpyr), 4.09 (qd,
3JH–H = 7.4 Hz,
3JH–P = 7.4 Hz, 8H, CH2O), 3.85 (s, 4H, NCH2-
Pyr), 2.93 (d, 2JH–P = 10.5 Hz, 4H, (EtO)2OPCH2N), 2.70 (q,
3JH–H = 7.1 Hz, 4H, CH3CH2N), 1.28 (t,
3JH–H = 7.1 Hz, 12H,
CH3CH2O), 1.03 (t,
3JH–H = 7.1 Hz, 6H, CH3CH2N).
13C NMR
(CDCl3, 75 MHz): δ 158.8 (Cpyr), 136.7 (Cpyr), 121.2 (Cpyr), 61.9
(d, 2JC–P = 6.8 Hz, CH2O), 61.2 (d,
3JC–P = 8.8 Hz, NCH2-Pyr),
49.4 (d, 1JC–P = 163.1 Hz, (EtO)2OPCH2N), 49.5 (d,
3JC–P =
8.8 Hz, CH3CH2N), 16.6 (d,
3JC–P = 6.1 Hz, CH3CH2O), 12.0
(CH3CH2N).
31P NMR (CDCl3, 161.9 MHz): δ 25.6 . ESI
+/MS
(MeOH): m/z = 493.2 ([M + H]+, 100%). Calc. for
C21H41N3O6P2·0.5 H2O: C, 50.19; H, 8.42; N, 8.36; Found: C,
50.11; H, 8.45; N, 8.52.
Procedure 2: To a mixture of 2,6-dibromomethylpyridine 2
(2 g, 7.55 mmol) and amine 7 (3.1 g, 15.85 mmol) in MeCN
(22 mL), under a nitrogen atmosphere, freshly flame-dried
K2CO3 (4 g, 30.2 mmol) was added. The reaction mixture was
heated at 50 °C overnight. After filtration, the solvent was
removed in vacuo and the crude oil was purified by flash
chromatography (CH2Cl2/MeOH). Compound 4 was obtained
as an oily light yellow product (878 mg, 24%).
(((Pyridine-2,6-diyl-bis(methylene))-bis(ethylazanediyl))-bis-
(methylene))diphosphonic acid L2. To a solution of com-
pound 4 (295 mg, 0.60 mmol) in CH2Cl2 (3 mL), TMSBr
(1.6 mL, 12.0 mmol) was added and the resulting mixture was
stirred at room temperature for 24 h. TMSBr (1.6 mL,
12.0 mmol) was added and the mixture was stirred at room
temperature for 24 h. The solvent was removed under reduced
pressure, the resulting residue was taken up with methanol
(5 mL) and the mixture was stirred at room temperature for
2 h. The evaporation–dissolution procedure was repeated with
methanol (5 mL) and the solution was stirred at room tempera-
ture for 24 h. The solvent was evaporated under reduced
pressure and the residue was dissolved in a minimum of
methanol. Addition of diethyl ether resulted in the formation
of a precipitate, which was collected by centrifugation and
dried under vacuum to aﬀord ligand L2 in 83% (240 mg). 1H
NMR (D2O, 200 MHz): δ 7.90 (t,
3JH–H = 7.7 Hz, 1H, Hpyr), 7.44
(d, 3JH–H = 8.0 Hz, 2H, Hpyr), 4.63 (s, 4H, NCH2-Pyr), 3.43 (q,
3JH–H = 7.3 Hz, 4H, CH3CH2N), 3.34 (d,
2JH–P = 12.4 Hz, 4H,
HO3PCH2N), 1.30 (t,
3JH–H = 7.1 Hz, 6H, CH3CH2N).
13C NMR
(D2O, 75 MHz): δ 149.8 (Cpyr), 139.9 (Cpyr), 124.2 (Cpyr), 57.6 (d,
Fig. 14 SPECT/CT images of a transgenic mouse with breast primary cancer, 5 minutes (left) and 25 minutes (right) after injection of 99mTc-L*-
MTn12.
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3JC–P = 4.5 Hz, NCH2-Pyr), 51.6 (d,
3JC–P = 3.8 Hz, CH3CH2N),
49.4 (d, 1JC–P = 136.5 Hz, HO3PCH2N), 8.2 (CH3CH2N).
31P NMR (D2O, 161.9 MHz): δ 8.4. ESI
−/MS (MeOH/H2O): m/z =
380.1 ([M – H]−, 100%). Calc. for C13H25N3O6P2·H2O·HBr: C,
32.51; H, 5.88; N, 8.75; Found: C, 31.92; H, 5.35; N, 8.34.
Diethyl-((benzyl(ethyl)amino)methyl)phosphonate 6. To a
mixture of N-ethylbenzylamine (5 mL, 33.6 mmol) and diethyl-
phosphite (5.7 mL, 43.6 mmol) at 0 °C, 6 mL (67.2 mmol) of
aqueous 37% formaldehyde was added. The resulting mixture
was warmed to room temperature and stirring was continued
at room temperature for 3 h. The reaction mixture was then
heated under reflux for 3 h. The solvents were removed under
reduced pressure and the resulting residue was purified by
flash chromatography (CH2Cl2/MeOH 97/3) to give compound
6 as a colorless oil (7.95 g; 83%). 1H NMR (CDCl3, 300 MHz):
δ 7.24–7.38 (m, 5H, HArom), 4.13 (qd,
3JH–H = 6.8 Hz,
3JH–P = 6.8
Hz, 4H, CH2O), 3.77 (s, 2H, CH2-Ph), 2.90 (d,
2JH–P = 10.6 Hz,
2H, (EtO)2OPCH2N), 2.71 (q,
3JH–H = 6.8 Hz, 2H, CH3CH2N),
1.33 (t, 3JH–H = 6.9 Hz, 6H, CH3CH2O), 1.08 (t,
3JH–H = 7.0 Hz,
3H, CH3CH2N).
13C NMR (CDCl3, 75 MHz): δ 138.3 (CArom),
128.3 (CArom), 127.5 (CArom), 126.4 (CArom), 61.1 (d,
2JC–P =
6.5 Hz, CH2O), 58.6 (d,
3JC–P = 8.8 Hz, CH2-Ph), 48.1 (d,
3JC–P =
8.1 Hz, CH3CH2N), 48.0 (d,
1JC–P = 161.9 Hz, (EtO)2OPCH2N),
15.9 (d, 3JC–P = 5.6 Hz, CH3CH2O), 11.2 (CH3CH2N).
31P NMR
(CDCl3, 161.9 MHz): δ 25.8. ESI
+/MS: m/z = 285.2 ([M]+•, 20%).
Calc. for C14H24NO3P·H2O: C, 55.43; H, 8.64; N, 4.62; Found:
C, 54.74; H, 8.35; N, 4.91.
Diethyl-((ethylamino)methyl)phosphonate 7. A solution of 6
(9 g, 31.5 mmol) in ethanol (100 mL) was hydrogenated in the
presence of Pd/C catalyst (0.9 g, 10% Pd). After 8 h at reflux,
the reaction was complete. The catalyst was filtered oﬀ and the
filtrate was evaporated to give compound 7 as a pale yellow oil
(6 g, 98%). 1H NMR (CDCl3, 300 MHz): δ 4.13 (m, 4H, CH2O),
2.99 (d, 2JH–P = 12.1 Hz, 2H, (EtO)2OPCH2N), 2.73 (q,
3JH–H =
6.8 Hz, 2H, CH3CH2N), 1.31 (t,
3JH–H = 6.8 Hz, 6H, CH3CH2O),
1.10 (t, 3JH–H = 7.0 Hz, 3H, CH3CH2N).
13C NMR (CDCl3,
75 MHz): δ 61.9 (d, 2JC–P = 7.2 Hz, CH2O), 45.3 (d,
3JC–P = 16.3
Hz, CH3CH2N), 43.6 (d,
1JC–P = 153.8 Hz, (EtO)2OPCH2N), 16.3
(d, 3JC–P = 5.4 Hz, CH3CH2O), 14.6 (CH3CH2N).
31P NMR
(CDCl3, 161.9 MHz): δ 25.9. ESI
+/MS (CH2Cl2): m/z = 196.1
([M + H]+, 42%), 413.2 ([2M + Na]+, 100%).
Tetraethyl-((((6-(bromomethyl)pyridin-2yl)methyl)azanediyl)-
bis(methylene))-bis(phosphonate) 8. To a mixture of 2,6-
dibromomethylpyridine 2 (3.2 g, 12.1 mmol) and tetra-ethyl
iminobis(methanephosphonate)20 (3.07 g, 9.66 mmol) in
MeCN under a nitrogen atmosphere, freshly flame-dried
K2CO3 (2.51 g, 18.15 mmol) was added. The reaction mixture
was heated at 50 °C overnight. After filtration, the solvent was
removed in vacuo and the crude oil was purified by flash
chromatography (CH2Cl2/MeOH 100/0 to 92/8). Compound 8
was obtained as an oily light yellow product (2.81 g, 58%). 1H
NMR (CDCl3, 300 MHz): δ 7.66 (t,
3JH–H = 7.8 Hz, 1H, Hpyr),
7.51 (d, 3JH–H = 8.1 Hz, 1H, Hpyr), 7.31 (d,
3JH–H = 8.1 Hz, 1H,
Hpyr), 4.51 (s, 2H, CH2Br), 4.11 (m, 10H, NCH2-Pyr, CH2O), 3.23
(d, 2JH–P = 9.9 Hz, 4H, (EtO)2OPCH2N), 1.29 (t,
3JH–H = 7.0 Hz,
12H, CH3CH2O).
13C NMR (CDCl3, 75 MHz): δ 158.7 (Cpyr),
155.9 (Cpyr), 137.4 (Cpyr), 122.9 (Cpyr), 121.9 (Cpyr), 62.0 (m,
NCH2-Pyr, CH2O), 50.3 (dd,
1JC–P = 157.9 Hz,
3JC–P = 8.2 Hz,
(EtO)2OPCH2N), 34.0 (CH2Br), 16.5 (m, CH3CH2O).
31P NMR
(CDCl3, 161.9 MHz): δ 24.4. ESI
+/MS (CH2Cl2): m/z = 502.8
([M + H]+, 14%), 504.8 ([M + H]+, 14%), 523.1 ([M + Na]+,
100%), 525.1 ([M + Na]+, 100%).
Hexaethyl-(((pyridine-2,6-diyl-bis(methylene))(ethylazanediyl))-
tris(methylene))-tris(phosphonate) 9. To a mixture of com-
pound 8 (2.81 g, 5.6 mmol) and amine 7 (1.31 g, 6.7 mmol) in
MeCN under a nitrogen atmosphere, freshly flame-dried
K2CO3 (1.55 g, 11.2 mmol) was added. The reaction mixture
was heated at 80 °C for 5 h. After filtration, the solvent was
removed in vacuo and the crude oil was purified by flash
chromatography (CH2Cl2/MeOH 96/4). Compound 9 was
obtained as an oily yellow product (1.81 g, 49%). 1H NMR
(CDCl3, 300 MHz): δ 7.54 (t,
3JH–H = 7.5 Hz, 1H, Hpyr), 7.34 (d,
3JH–H = 8.2 Hz, 2H, Hpyr), 4.08–3.97 (m, 12H, CH2O), 3.79 (s,
4H, NCH2-Pyr), 3.13 (d,
2JH–P = 9.2 Hz, 2H, (EtO)2OPCH2NEt),
2.87 (d, 2JH–P = 10.8 Hz, 4H, [(EtO)2OPCH2]2N), 2.62 (q,
3JH–H =
7.0 Hz, 2H, CH3CH2N), 1.20 (t,
3JH–H = 6.7 Hz, 18H, CH3CH2O),
0.96 (t, 3JH–H = 7.3 Hz, 3H, CH3CH2N).
13C NMR (CDCl3,
75 MHz): δ 158.9 (Cpyr), 157.7 (Cpyr), 136.9 (Cpyr), 121.8 (Cpyr),
121.6 (Cpyr), 62.6 (t,
3JC–P = 8.0 Hz, NCH2-Pyr), 62.0 (d,
2JC–P =
6.5 Hz, CH2O), 62.0 (d,
2JC–P = 8.6 Hz, CH2O), 61.0 (d,
3JC–P =
8.6 Hz, NCH2-Pyr), 50.2 (dd,
1JC–P = 158.4 Hz,
3JC–P = 8.7 Hz,
[(EtO)2OPCH2]2N), 49.4 (d,
3JC–P = 8.9 Hz, CH3CH2N), 49.3 (d,
1JC–P = 163.3 Hz, (EtO)2OPCH2NEt), 16.5 (m, CH3CH2O), 11.9
(CH3CH2N).
31P NMR (CDCl3, 161.9 MHz): δ 24.4, 25.4. ESI
+/
MS (CH2Cl2): m/z = 616.3 ([M + H]
+, 100%). Calc. for
C24H48N3O9P3·2H2O: C, 44.24; H, 8.04; N, 6.45; Found: C,
43.88; H, 7.79; N, 6.62.
(((Pyridine-2,6-diyl-bis(methylene))(ethylazanediyl))-tris-
(methylene))triphosphonic acid L3. To a solution of com-
pound 9 (1.81 g, 2.93 mmol) in CH2Cl2 (10 mL), TMSBr
(11.62 mL, 88 mmol) was added at 0 °C, and the resulting
mixture was stirred at room temperature for 24 h. TMSBr
(11.6 mL, 88 mmol) was added and the mixture was stirred at
room temperature for 24 h. The solvent was removed, the
resulting residue was taken up with methanol (10 mL) and the
mixture was stirred at room temperature for 2 h. The evapor-
ation–dissolution procedure was repeated with methanol
(10 mL) and the solution was stirred at room temperature for
24 h. The solvent was evaporated under reduced pressure and
the residue was dissolved in a minimum of methanol.
Addition of diethyl ether resulted in the formation of a precipi-
tate, which was collected by centrifugation and dried under
vacuum to aﬀord ligand L3 (1.71 g, 90%). 1H NMR (D2O +
NaOD, 200 MHz): δ 7.68 (t, 3JH–H = 7.4 Hz, 1H, Hpyr), 7.44 (d,
3JH–H = 7.4 Hz, 1H, Hpyr), 7.29 (d,
3JH–H = 6.7 Hz, 1H, Hpyr), 3.90
(s, 2H, NCH2-Pyr), 3.84 (s, 2H, NCH2-Pyr), 2.54 (m, 8H,
O3PCH2N, CH3CH2N), 0.85 (t,
3JH–H = 7.4 Hz, 3H, CH3CH2N).
13C NMR (D2O, 75 MHz): δ 159.0 (Cpyr), 158.2 (Cpyr), 138.0
(Cpyr), 123.0 (Cpyr), 122.6 (Cpyr), 62.5 (m, NCH2-Pyr), 60.2 (d,
3JC–P = 6.0 Hz, NCH2-Pyr), 55.4 (dd,
1JC–P = 145.9 Hz,
3JC–P = 8.8
Hz, [HO3PCH2]2N), 52.6 (d,
1JC–P = 138.9 Hz, HO3PCH2NEt),
48.1 (d, 3JC–P = 8.0 Hz, CH3CH2N), 10.5 (CH3CH2N).
31P NMR
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(D2O, 161.9 MHz): δ 17.1, 16.5. ESI
−/MS (D2O): m/z = 446.1
([M – H]−, 100%). Calc. for C12H24N3O9P3·2H2O·2HBr: C, 22.34;
H, 4.69; N, 6.51; Found: C, 22.80; H, 4.81; N, 6.24.
Diethyl-(((6-bromomethyl)pyridine-2-yl)methyl)phosphonate
10. Compound 2 (480 mg, 1.81 mmol) was dissolved in
triethyl phosphite (315 μL, 1.81 mmol) under a nitrogen
atmosphere. The mixture was heated at 50 °C, protected from
light, for 4 days. After cooling at room temperature, excess
triethyl phosphite was removed under high vacuum. The crude
product was purified by flash chromatography (CH2Cl2/MeOH
94/6). Compound 10 was isolated as an orange oil (281 mg,
48%). Compound 10 is not stable and is rapidly degraded. 1H
NMR (CDCl3, 300 MHz): δ 7.55 (t,
3JH–H = 7.8 Hz, 1H, Hpyr),
7.21 (d, 3JH–H = 7.8 Hz, 2H, Hpyr), 4.42 (s, 2H, CH2Br), 3.98 (qd,
3JH–H = 7.1 Hz,
3JH–P = 7.1 Hz, 4H, CH2O), 3.30 (d,
2JH–P = 21.6
Hz, 2H, (EtO)2OPCH2), 1.20 (t,
3JH–H = 7.0 Hz, 6H, CH3CH2O).
13C NMR (CDCl3, 75 MHz): δ 155.7 (d, JC–P = 2.7 Hz, Cpyr),
152.0 (d, JC–P = 8.3 Hz, Cpyr), 136.7 (d, JC–P = 2.2 Hz, Cpyr), 122.8
(d, JC–P = 5.0 Hz, Cpyr), 120.9 (d, JC–P = 2.6 Hz, Cpyr), 61.4 (d,
2JC–P = 6.5 Hz, CH2O), 35.7 (d,
1JC–P = 134.3 Hz, (EtO)2OPCH2),
33.2 (CH2Br), 15.6 (d,
3JC–P = 5.7 Hz, CH3CH2O).
31P NMR
(CDCl3, 161.9 MHz): δ 24.4.
Tetraethyl-((((6-(diethylmethylenephosphonate)pyridin-2yl)-
methyl)azanediyl)-bis(methylene))-bis(phosphonate) 11. To a
mixture of compound 10 (800 mg, 2.5 mmol) and amine 7
(790 mg, 2.5 mmol) in MeCN under a nitrogen atmosphere,
freshly flame-dried K2CO3 (684 mg, 4.95 mmol) was added.
The reaction mixture was heated at 80 °C, protected from light,
for 48 h. After filtration, the solvent was removed in vacuo and
the crude product was purified by flash chromatography
(CH2Cl2/MeOH 100/0 to 96/4). Compound 11 was obtained as
an oily product (476 mg, 32%). 1H NMR (CDCl3, 300 MHz): δ
7.60 (t, 3JH–H = 8.4 Hz, 1H, Hpyr), 7.45 (d,
3JH–H = 7.9 Hz, 1H,
Hpyr), 7.25 (d,
3JH–H = 7.5 Hz, 1H, Hpyr), 4.07 (m, 14H, CH2O,
NCH2-Pyr), 3.36 (d,
2JH–P = 22.0 Hz, 2H, (EtO)2OPCH2), 3.20 (d,
2JH–P = 10.4 Hz, 4H, [(EtO)2OPCH2]2N), 1.28 (t,
3JH–H = 7.1 Hz,
12H, CH3CH2O), 1.24 (t,
3JH–H = 7.1 Hz, 6H, CH3CH2O).
13C
NMR (CDCl3, 75 MHz): δ 158.4 (d, JC–P = 2.1 Hz, Cpyr), 151.9 (d,
JC–P = 8.2 Hz, Cpyr), 137.0 (d, JC–P = 2.4 Hz, Cpyr), 122.8 (d, JC–P =
4.8 Hz, Cpyr), 121.8 (d, JC–P = 3.3 Hz, Cpyr), 62.5 (t,
3JC–P = 7.9
Hz, NCH2-Pyr), 62.2 (d,
2JC–P = 6.6 Hz, CH2O), 62.1 (m, CH2O),
50.4 (dd, 1JC–P = 159.2 Hz,
3JC–P = 8.3 Hz, [(EtO)2OPCH2]2N),
36.6 (d, 1JC–P = 135.1 Hz, (EtO)2OPCH2), 16.5 (m, CH3CH2O).
31P NMR (CDCl3, 161.9 MHz): δ 25.1, 24.4. ESI
+/MS (CH2Cl2):
m/z = 559.2 ([M + H]+, 100%). Calc. for C21H41N2O9P3·2H2O: C,
42.43; H, 7.63; N, 4.71; Found: C, 42.90; H, 7.03; N, 5.06.
((((6-(Methylene)pyridin-2yl)methyl)azanediyl)-bis(methyl-
ene))triphosphonic acid L4. Compound 11 (190 mg,
0.34 mmol) was dissolved in 6 M HCl (6 mL) and the mixture
was heated at reflux overnight. The solvent was evaporated
under reduced pressure and the residue was dissolved in a
minimum of methanol. Addition of diethyl ether resulted in
the formation of a precipitate, which was collected by centrifu-
gation and dried under vacuum to give ligand L4 (60 mg,
46%). 1H NMR (D2O, 200 MHz): δ 8.39 (t,
3JH–H = 7.9 Hz, 1H,
Hpyr), 7.90 (d,
3JH–H = 7.9 Hz, 1H, Hpyr), 7.84 (d,
3JH–H = 7.9 Hz,
1H, Hpyr), 4.71 (s, 2H, NCH2-Pyr), 3.51 (d,
2JH–P = 21.2 Hz, 2H,
HO3PCH2), 3.35 (d,
2JH–P = 12.0 Hz, 4H, [HO3PCH2]2N).
13C
NMR (D2O, 100 MHz): δ 151.9 (Cpyr), 148.5 (Cpyr), 146.2 (Cpyr),
127.7 (d, JC–P = 4.3 Hz, Cpyr), 125.7 (Cpyr), 56.6 (m, NCH2-Pyr),
52.6 (dd, 1JC–P = 144.7 Hz,
3JC–P = 5.8 Hz, [HO3PCH2]2N), 34.8
(d, 1JC–P = 123.4 Hz, HO3PCH2).
31P NMR (D2O, 161.9 MHz): δ
13.7. ESI−/MS (D2O): m/z = 389.0 ([M − H]−, 100%). Calc. for
C9H17N2O9P3·HCl: C, 25.34; H, 4.25; N, 6.56; Found: C, 25.07;
H, 4.32; N, 6.40.
MALDI-MS analyses
Prior to analysis, the MTn12 antibodies, either uncoupled or
coupled to the BFC chelate, were desalted on a C18 ZipTip
(Millipore). Ten µg of antibody were loaded and then eluted in
2 μL MeCN 80%/TFA 0.1%. The whole eluate was spotted on
the target plate with 0.6 μL of sinapinic acid (saturated solu-
tion diluted 3 times in MeCN 50%/TFA 0.1%). The mass
spectrometer (Autoflex, Bruker Daltonics) was operated in posi-
tive linear mode, with BSA as a calibrant.
Production and purification of MTn12 antibody. The
MTn12 anti-tenascin-C mouse antibody69 was purified from
hybridoma culture supernatants by aﬃnity chromatography
using a HiTrap protein G sepharose column and an AktaPrime
purification system (GE Healthcare).
The labeling experiment was carried out on 500 μg (500 μL
of a 1 mg mL−1 solution in PBS) of the antibody MTn12 to
which 2 mg of solid BFC L* (2.7 μmol) was added, corres-
ponding to 800 equivalents of the ligand for the antibody. The
reaction medium was adjusted to a pH of 7.4 with 200 mM
NH4HCO3 and was stirred for 2 h at room temperature. The
reaction medium was purified repeatedly to eliminate the
excess of ligand with PBS using Vivaspin500 (Sartorius)
modules with a 30 kDa cut-oﬀ (500 μL of PBS per cycle; 20
cycles).
Immunostaining experiment. Immunofluorescence analysis
of murine insulinoma tumors was performed by staining pan-
creata sections from RIP1-Tag2 mice as previously described.70
The MTn12 antibody, either coupled to the BFC chelate or
uncoupled, was incubated overnight at 4 °C on tissue sections
(2 µg mL−1), and a Cy3-coupled anti-rat secondary antibody
(1/1600 for 1 h at room temperature; Interchim) was used for
detection. Cell nuclei were stained with DAPI. Negative con-
trols were performed by omitting the primary antibody.
SPECT animal imaging. All work performed on animals was
in accordance with the local ethics committee following the
rules (agreement number AL/05/12/02/13 of the regional
ethical committee). Biodistribution of the 99mTc complexes of
ligands L1 and L2 was obtained by tail vein injection of the
complexes. Transgenic breast cancer mice (MMTV-NeuNT TG.
NK line)73 in the FVB background were obtained by breeding
MMTV-NeuNT male with wild-type FVB female mice. Genotyp-
ing was performed on DNA extracted from tail as previously
described,70 using two primer pairs specific to the NeuNT
(forward1:GGAAGTACCCGGATGAGGAGGGCATATG, and
reverse1: CCGGGCAGCCAGGTCCCTGTGTACAAGCCG; forward2:
TCCTGTGTGGATCTGGATGA, and reverse2: GTCAGCGGCTC-
Organic & Biomolecular Chemistry Paper
This journal is © The Royal Society of Chemistry 2014 Org. Biomol. Chem., 2014, 12, 9601–9620 | 9617
CACTAACTC). Female mice with macroscopically visible primary
tumors were used three months after the palpation of the first
primary tumor for intravenous injection of the labeled 99mTc-
L*-MTn12 antibody in the lateral tail vein and in vivo imaging
by SPECT.
In vivo CT/SPECT analysis. In order to recognize the
diﬀerent organs, prior to SPECT analysis, a CT image was
recorded on the AMISSA platform, a home-made multimodal-
ity imaging system for small animals combining X-ray, SPECT
and PET devices. The µCT delivered a 3D reconstructed
volume of the animal in real time.77
Targeting of 99mTc-labeled molecules was monitored via the
µSPECT imaging technique. Mice were anesthetized by intra-
peritoneal injection of 10 µl g−1 of a solution made with keta-
mine hydrochloride 10% (Imalgene, Centravet, Velaine en
Haye, France) and Xylazine 5% (Rompun, Centravet, Velaine
en Haye, France) and placed in prone position in the animal
holder after injection in the tail vein. µSPECT imaging was per-
formed 4 minutes post-intravenous injection of 124 MBq,
118 MBq and 59 MBq in 220 µL, 200 µL and 100 µL of 99mTc
molecules for L1, L2 and L*-MTn12, respectively, injected in
the tail vein. The µSPECT system consists of a four head detec-
tion gamma camera. Each head comprises five separated
detection modules arranged along a circle of 58 mm with the
pinhole as the center. A detection module consists of a
YAP : Ce matrix of 8 × 8 scintillating crystals 2.3 × 2.3 × 28 mm3
each coupled to a multi-anode photomultiplier 8 × 8 (Hama-
matsu H 8804). The distance from the pinhole to the axis of
rotation is 28 mm and the distance between the pinhole and
the crystal is 58 mm which results in a magnification factor of
2.07.78 Images were reconstructed using the OSEM (Ordered
Subset Expectation Maximisation) iterative algorithm adapted
for pinhole imaging. Images were viewed and quantified using
the Anatomist freeware (http://brainvisa.info/index_f.html).
General protocol for radiolabeling
Ligand L1 (5 mg) or ligand L2 (4.5 mg) were dissolved in water
(1 mL). Sodium ascorbate (150 μL, 5 mg mL−1) and stannous
chloride (75 μL, 2 mg mL−1) in 0.1 M hydrochloric acid were
then added to the above solution. The pH of the resulting solu-
tion was adjusted to 6.5–7.0 with 1 M NaOH. Freshly eluted
99mTcO4
− (1 mL, 600–700 MBq mL−1) was added, and the
resulting mixture was then stirred at room temperature for
30 min for optimum labelling yield.
The labeling eﬃciency was estimated chromatographically
using ITLC-SG strips as the stationary phase and acetone as
the mobile phase. After developing the TLC, it was cut into two
equal halves and radioactivity of each segment was determined
in a well-type γ-ray counter. The free 99mTcO4− moved with the
solvent, while the radiolabeled formulation remained at the
point of application.
L* was labeled with 99mTc using 99mTc-glucoheptonate as
an intermediate. Briefly, 99mTcO4
− (1.4 GBq in 400 μL) was
added to a solution containing 50 μL sodium glucoheptonate
(10 mg ml−1) and 150 μL SnCl2 (2 mg mL−1 in 0.1 M HCl).
This solution is then added to the vial containing the L*
labeled MTn12 antibody (250 μL at 1.8 mg mL−1 in PBS, pH
7.4). The labeling reaction was completed after 30 min with
slow stirring at room temperature.
The mixture was purified by centrifugation at 13 000 RPM
over 30 000 MW cutoﬀ filtering devices (Amicon Ultra 0.5 mL
centrifugal filters, Millipore).
The radiochemical purity of 99mTc-L*-MTn12 was estimated
to be more than 95% by instant thin layer chromatography
(ITLC). 99mTc-L*-MTn12 remains immobile, and other species
(99mTc-glucoheptonate and 99mTcO4
−) are mobile when satu-
rated saline was used as a developing solvent.
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